

OK TO ENTER: /M.B./

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :
MARIE-CLAUDE GINGRAS, ET AL. : EXAMINER: BELYAVSKYI
SERIAL NO: 10/021,509 :
FILED: DECEMBER 7, 2001 : GROUP ART UNIT: 1644
FOR: TREM-1 SPLICE VARIANT FOR :
USE IN MODIFYING IMMUNE
RESPONSES

AMENDMENT AFTER ALLOWANCE

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

This amendment after allowance as provided by 37 C.F.R. § 1.132 is rendered necessary to clarify the discrepancy found between our records of agreements with the examiner as stated in the applicant Interview Summaries of the examiner initiated interviews of October 14 and October 15 (both of records) and the Notice of Allowance dated of 10/20/2010.

REMARKS/ ARGUMENTS

The amendment found in the Notice of Allowance amends Claim 1 as follow: “A method of modulating an immune response including administering to an animal, in need thereof, a composition comprising a soluble polypeptide of SEQ ID NO: 2, or a fragment thereof, wherein said fragment consist of amino acid 1-136 of SEQ ID NO: 2, in an amount